PMC:6582309 / 52315-54413 JSONTXT

{"project":"2_test","denotations":[{"id":"31249505-25609634-38601741","span":{"begin":293,"end":297},"obj":"25609634"},{"id":"31249505-9307048-38601742","span":{"begin":429,"end":433},"obj":"9307048"},{"id":"31249505-8771606-38601743","span":{"begin":574,"end":578},"obj":"8771606"},{"id":"31249505-19753696-38601744","span":{"begin":597,"end":601},"obj":"19753696"},{"id":"31249505-15795058-38601745","span":{"begin":621,"end":625},"obj":"15795058"},{"id":"31249505-22004509-38601746","span":{"begin":718,"end":722},"obj":"22004509"},{"id":"31249505-11108188-38601747","span":{"begin":938,"end":942},"obj":"11108188"},{"id":"31249505-15795058-38601748","span":{"begin":962,"end":966},"obj":"15795058"},{"id":"31249505-15795058-38601749","span":{"begin":1178,"end":1182},"obj":"15795058"},{"id":"31249505-15795058-38601750","span":{"begin":1305,"end":1309},"obj":"15795058"},{"id":"31249505-15795058-38601751","span":{"begin":1514,"end":1518},"obj":"15795058"},{"id":"31249505-30224383-38601754","span":{"begin":1770,"end":1774},"obj":"30224383"},{"id":"31249505-17055614-38601755","span":{"begin":1866,"end":1870},"obj":"17055614"},{"id":"31249505-22005070-38601756","span":{"begin":1889,"end":1893},"obj":"22005070"},{"id":"31249505-18385314-38601757","span":{"begin":2050,"end":2054},"obj":"18385314"},{"id":"31249505-25531153-38601758","span":{"begin":2075,"end":2079},"obj":"25531153"},{"id":"31249505-27776266-38601759","span":{"begin":2094,"end":2098},"obj":"27776266"}],"text":"TABLE 3 Pharmacological interventions tested in dogs with cognitive decline.\nName/type Mode of action Testing in dog Results/outcomes References\nLY2886721 BACE1 inhibitor Pharmacology study in dogs and clinical trial in healthy volunteers Aβ lowering in plasma and CSF May et al.,2015\nSelegiline (L-deprenyl) MAOB inhibitor Longitudinal study Higher life expectancy (cognitive status not monitored) Ruehl et al.,1997\nSelegiline (L-deprenyl) MAOB inhibitor Performance studies Improved visuospatial working memory (in only a subset of dogs) Head et al., 1996; Campbell et al., 2001; Studzinski et al.,2005\nAtorvastatin Reduction of Aβ and BACE1 Longitudinal study Neuroprotective Barone et al.,2012\nAdrafinil A wakefulness-promoting agent (eugeroic) with nootropic effects Longitudinal study; pharmacological study A significant increase in locomotion; improved learning; impaired working memory Siwak et al., 2000; Studzinski et al.,2005\nAmpakine Positive modulator of AMPA receptors (enhance excitatory glutamatergic neurotransmission) Pharmacological study Decrease of performance accuracy; may have memory impairing effects Studzinski et al.,2005\nCP-118,954 Acetylcholinesterase inhibitor Pharmacological study Minimal cognitive enhancing effects Studzinski et al.,2005\nPhenserine Acetylcholinesterase inhibitor Pharmacological study; performance study Enhancing effects on memory and learning; improved performance (only in a subset of dogs treated) Studzinski et al., 2005; Araujo et al.,2011a\nDonepezil Acetylcholinesterase inhibitor Performance study memory enhancement Araujo et al.,2011a\nCNP520 BACE1 inhibitor Dogs, human Safe to use in dogs; tolerated in healthy humans; ongoing clinical trials Neumann et al.,2018\nAntioxidant-rich diet with cognitive enrichment / Dogs Improved cognition Opii et al., 2008; Dowling and Head,2012\nAnti-Aβ immunotherapy Passive vaccination with injections of antibodies against Aβ42 Dogs Reduced amyloid plaques and reduced astrogliosis Head et al., 2008; Neus Bosch et al., 2015; Davis et al.,2017"}

{"project":"0_colil","denotations":[{"id":"31249505-25609634-737166","span":{"begin":293,"end":297},"obj":"25609634"},{"id":"31249505-9307048-737167","span":{"begin":429,"end":433},"obj":"9307048"},{"id":"31249505-8771606-737168","span":{"begin":574,"end":578},"obj":"8771606"},{"id":"31249505-19753696-737169","span":{"begin":597,"end":601},"obj":"19753696"},{"id":"31249505-15795058-737170","span":{"begin":621,"end":625},"obj":"15795058"},{"id":"31249505-22004509-737171","span":{"begin":718,"end":722},"obj":"22004509"},{"id":"31249505-11108188-737172","span":{"begin":938,"end":942},"obj":"11108188"},{"id":"31249505-15795058-737173","span":{"begin":962,"end":966},"obj":"15795058"},{"id":"31249505-15795058-737174","span":{"begin":1178,"end":1182},"obj":"15795058"},{"id":"31249505-15795058-737175","span":{"begin":1305,"end":1309},"obj":"15795058"},{"id":"31249505-15795058-737176","span":{"begin":1514,"end":1518},"obj":"15795058"},{"id":"31249505-30224383-737179","span":{"begin":1770,"end":1774},"obj":"30224383"},{"id":"31249505-17055614-737180","span":{"begin":1866,"end":1870},"obj":"17055614"},{"id":"31249505-22005070-737181","span":{"begin":1889,"end":1893},"obj":"22005070"},{"id":"31249505-18385314-737182","span":{"begin":2050,"end":2054},"obj":"18385314"},{"id":"31249505-25531153-737183","span":{"begin":2075,"end":2079},"obj":"25531153"},{"id":"31249505-27776266-737184","span":{"begin":2094,"end":2098},"obj":"27776266"}],"text":"TABLE 3 Pharmacological interventions tested in dogs with cognitive decline.\nName/type Mode of action Testing in dog Results/outcomes References\nLY2886721 BACE1 inhibitor Pharmacology study in dogs and clinical trial in healthy volunteers Aβ lowering in plasma and CSF May et al.,2015\nSelegiline (L-deprenyl) MAOB inhibitor Longitudinal study Higher life expectancy (cognitive status not monitored) Ruehl et al.,1997\nSelegiline (L-deprenyl) MAOB inhibitor Performance studies Improved visuospatial working memory (in only a subset of dogs) Head et al., 1996; Campbell et al., 2001; Studzinski et al.,2005\nAtorvastatin Reduction of Aβ and BACE1 Longitudinal study Neuroprotective Barone et al.,2012\nAdrafinil A wakefulness-promoting agent (eugeroic) with nootropic effects Longitudinal study; pharmacological study A significant increase in locomotion; improved learning; impaired working memory Siwak et al., 2000; Studzinski et al.,2005\nAmpakine Positive modulator of AMPA receptors (enhance excitatory glutamatergic neurotransmission) Pharmacological study Decrease of performance accuracy; may have memory impairing effects Studzinski et al.,2005\nCP-118,954 Acetylcholinesterase inhibitor Pharmacological study Minimal cognitive enhancing effects Studzinski et al.,2005\nPhenserine Acetylcholinesterase inhibitor Pharmacological study; performance study Enhancing effects on memory and learning; improved performance (only in a subset of dogs treated) Studzinski et al., 2005; Araujo et al.,2011a\nDonepezil Acetylcholinesterase inhibitor Performance study memory enhancement Araujo et al.,2011a\nCNP520 BACE1 inhibitor Dogs, human Safe to use in dogs; tolerated in healthy humans; ongoing clinical trials Neumann et al.,2018\nAntioxidant-rich diet with cognitive enrichment / Dogs Improved cognition Opii et al., 2008; Dowling and Head,2012\nAnti-Aβ immunotherapy Passive vaccination with injections of antibodies against Aβ42 Dogs Reduced amyloid plaques and reduced astrogliosis Head et al., 2008; Neus Bosch et al., 2015; Davis et al.,2017"}